Synthesis, cardiac electrophysiology, and .beta.-blocking activity of novel arylpiperazines with potential as class II/III antiarrhythmic agents
Citations Over TimeTop 15% of 1992 papers
Abstract
A series of novel arylpiperazines have been prepared in an attempt to incorporate both class II (beta-receptor blocking) and class III antiarrhythmic properties in a single molecule. The key step in the preparation of the new compounds involves a regioselective heterocyclic ring formation. All but four compounds significantly prolonged action potential duration in canine cardiac Purkinje fibers (class III activity). All but one of the compounds demonstrated beta-receptor affinity in a competitive binding assay and three had beta 1-receptor selectivity. Compared to sotalol, a reference class II/III agent, arylpiperazine 7a (4-[(methylsulfonyl)amino]-N-[(4- phenylpiperazin-2-yl)methyl]benzamide) demonstrated beta 1-selectivity and was 1 order of magnitude more potent in the in vitro class III and the beta 1-receptor screens. Compound 7a was evaluated further and found to be effective in preventing programmed electrical stimulation-induced arrhythmias in conscious dogs (class III activity) and against epinephrine-induced arrhythmias in halothane anesthetized dogs (class II activity).
Related Papers
- → Discovery and optimization of piperidyl benzamide derivatives as a novel class of 11β-HSD1 inhibitors(2009)29 cited
- Note Synthesis and antibacterial activity of benzamides and sulfonamide derived from 2- amino-5-bromo/nitropyridine against bacterial strains isolated from clinical patients(2011)
- → N-(4-Methylphenyl)benzamide(2007)7 cited
- → Synthesis of N‐(2,3‐dihydro‐1‐[14C]methyl‐2‐oxo‐5‐phenyl‐1H‐1,4‐benzodiazepin‐3‐yl)‐benzamide and N‐(2,3‐dihydro‐1‐[14C]methyl‐2‐oxo‐5‐phenyl‐1H‐1,4‐benzodiazepin‐3‐yl)‐N‐[14C]methyl‐benzamide as novel carbon‐14 labelled CCK antagonists(2002)6 cited
- → N-(2,4-Dichlorophenyl)benzamide(2008)6 cited